Expanding the reach of highly potent cancer therapies with pre|CISION^®

We believe in hope
without compromise

The pre|CISION^® peptide drug conjugate platform. >

Avacta is seeking to expand its partnerships for targeted cancer therapies. >

We’re delighted to be shortlisted as a finalist at the 2024 Scrip Awards in the ‘Best Oncology R&D Advance’ category >